303 related articles for article (PubMed ID: 24800651)
1. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.
Wilmot HV; Hogwood J; Gray E
Haemophilia; 2014 Nov; 20(6):891-7. PubMed ID: 24800651
[TBL] [Abstract][Full Text] [Related]
2. Calibration of the WHO 5th IS for Blood Coagulation Factor IX, Concentrate and Ph. Eur. Human Coagulation Factor IX Concentrate Biological Reference Preparation Batch 3 and investigation of the suitability of an IS as potency standard for purified full-length recombinant FIX.
Gray E; Hogwood J; Dougall T; Rigsby P; Matejtschuk P; Terao E
Pharmeur Bio Sci Notes; 2021; 2021():26-68. PubMed ID: 33783349
[TBL] [Abstract][Full Text] [Related]
3. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
Bowyer AE; Hillarp A; Ezban M; Persson P; Kitchen S
J Thromb Haemost; 2016 Jul; 14(7):1428-35. PubMed ID: 27107268
[TBL] [Abstract][Full Text] [Related]
4. Potency estimates for recombinant factor IX in the one-stage clotting assay are influenced by more than just the choice of activated partial thromboplastin time reagent.
Wilmot HV; Gray E
Haemophilia; 2018 Sep; 24(5):e363-e368. PubMed ID: 30051554
[TBL] [Abstract][Full Text] [Related]
5. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
[TBL] [Abstract][Full Text] [Related]
6. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays.
Horn C; Négrier C; Kalina U; Seifert W; Friedman KD
J Thromb Haemost; 2019 Jan; 17(1):138-148. PubMed ID: 30418692
[TBL] [Abstract][Full Text] [Related]
7. [Factor IX assays in treated hemophilia B patients].
Pouplard C; Jeanpierre E; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Ternisien C; Toulon P; Voisin S; Nougier C;
Ann Biol Clin (Paris); 2019 Feb; 77(1):41-52. PubMed ID: 30799297
[TBL] [Abstract][Full Text] [Related]
8. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing.
Björkman S
Haemophilia; 2011 Mar; 17(2):179-84. PubMed ID: 21299739
[TBL] [Abstract][Full Text] [Related]
9. Recombinant FIX Fc fusion protein activity assessment with the one-stage clotting assay: A multicenter, assessor-blinded, prospective study in Japan (J-Field Study).
Fukutake K; Kobayashi T; Sommer JM; Hirakata T
Int J Lab Hematol; 2020 Apr; 42(2):162-169. PubMed ID: 31820573
[TBL] [Abstract][Full Text] [Related]
10. Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.
Nummi V; Jouppila A; Lassila R
Int J Lab Hematol; 2017 Aug; 39(4):359-368. PubMed ID: 28406575
[TBL] [Abstract][Full Text] [Related]
11. Collaborative study for the establishment of replacement batches for human coagulation factor IX concentrate reference standards.
Gray E; Pickering W; Hockley J; Rigsby P; Weinstein M; Terao E; Buchheit KH
Pharmeuropa Bio; 2008 Dec; 2008(1):19-30. PubMed ID: 19220978
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.
Alamelu J; Bevan D; Sorensen B; Rangarajan S
J Thromb Haemost; 2014 Dec; 12(12):2044-8. PubMed ID: 25315324
[TBL] [Abstract][Full Text] [Related]
13. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
Tiefenbacher S; Bohra R; Amiral J; Bowyer A; Kitchen S; Lochu A; Rosén S; Ezban M
J Thromb Haemost; 2017 Oct; 15(10):1901-1912. PubMed ID: 28772338
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.
Brinkhous KM; Sigman JL; Read MS; Stewart PF; McCarthy KP; Timony GA; Leppanen SD; Rup BJ; Keith JC; Garzone PD; Schaub RG
Blood; 1996 Oct; 88(7):2603-10. PubMed ID: 8839853
[TBL] [Abstract][Full Text] [Related]
15. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations.
Barrowcliffe TW; Raut S; Sands D; Hubbard AR
Semin Thromb Hemost; 2002 Jun; 28(3):247-56. PubMed ID: 12098084
[TBL] [Abstract][Full Text] [Related]
16. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
[TBL] [Abstract][Full Text] [Related]
17. Real-world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples.
Sommer JM; Sadeghi-Khomami A; Barnowski C; Wikén M; Willemze AJ
Int J Lab Hematol; 2020 Jun; 42(3):350-358. PubMed ID: 32202380
[TBL] [Abstract][Full Text] [Related]
18. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
Roth DA; Kessler CM; Pasi KJ; Rup B; Courter SG; Tubridy KL;
Blood; 2001 Dec; 98(13):3600-6. PubMed ID: 11739163
[TBL] [Abstract][Full Text] [Related]
19. Activity measurements of dalcinonacog alfa.
Williams SC; Gray E
Haemophilia; 2020 Mar; 26(2):346-353. PubMed ID: 32142203
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX.
Collins PW; Møss J; Knobe K; Groth A; Colberg T; Watson E
J Thromb Haemost; 2012 Nov; 10(11):2305-12. PubMed ID: 22998153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
